the program committee is pleased to announce that we are now accepting late-breaking submissions for poster-only presentation.

To access the submission system, browse: https://www.xcdsystem.com/srsweb/member

12 Jan 2019 Late-breaking Abstract Submission Opens

15 Feb 2019 Late-breaking Abstract Submission Closes

The greatest strength of the ISRS symposium series is the interaction between attendees. Key to this interaction is presenting your own research at the meeting. We expect to receive hundreds of abstract submissions from researchers working in over 40 different countries. Of these, nearly 90 will be accepted for oral presentation. The remainder will be presented as posters, with some of these being presented during our "rapid-fire poster presentations" (1-2 minute talks before the general audience).

As has been our long tradition, all abstracts will be published in the Journal of Labelled Compounds and Radiopharmaceuticals (JLCR).

Abstract Submission Specifics

  • The body of the abstract is limited to 650 words; this includes any words used in tables as part of the abstract body.

  • Abstract title and author/affiliation information do not count against he 650 word total.

  • Only one .JPG image may be uploaded, though you may combine up to three images into one .JPG file. Images will be displayed electronically in color, but grayscale (black & white) in the print version of JLCR.

  • You are strongly encouraged to organize your abstract according to the standard subtitles: Objectives, Methods, Results, Conclusions, Acknowledgments, and References.

  • You are also strongly encouraged to follow the nomenclature guidelines recently published by an international working group.

  • Use only one table in the body of your abstract or, possibly, two small tables.

  • The goal is to print each abstract on one page.

  • Abstracts must include actual data and not simply be overviews.

  • If the abstract refers to a compound, the compound should be properly identified (not simply a number).

  • The structure of novel compounds should be discussed in the acceptable abstract.

If you have any questions, please contact Charles Metzger - cmetzger(a)srsweb.org.